NO981127L - Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer - Google Patents

Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer

Info

Publication number
NO981127L
NO981127L NO981127A NO981127A NO981127L NO 981127 L NO981127 L NO 981127L NO 981127 A NO981127 A NO 981127A NO 981127 A NO981127 A NO 981127A NO 981127 L NO981127 L NO 981127L
Authority
NO
Norway
Prior art keywords
igf
related tumors
treatment
jgf
insulin
Prior art date
Application number
NO981127A
Other languages
English (en)
Other versions
NO981127D0 (no
Inventor
Leonard Buckbinder
Nikolai A Kley
Bernd R Seizinger
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO981127D0 publication Critical patent/NO981127D0/no
Publication of NO981127L publication Critical patent/NO981127L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Metoder for å behandle p53-relaterte tumorer ved tilførsel av (1) en modulator av IGF-BP3, der modulatoren oppregulerer IGF-BP3 ekspresjon eller aktivitet; (2) IGF-BP3 selv; eller (3) en ekspresjonsvektor som omfatter en nukleotidsekvens som koder for IGF-BP3. l den senere metoden kan IGF-BP3 nukleotid-sekvensene også være operativt koplet til en induserbar promoter eller enhancer, der metoden videre omfatter tilførsel av en induserende komponent som har evne til å initiere eller oppregulere ekspresjon av proteinet. Videre kan enhver av de foregående metoder inkluderes som et ytterligere trinn tilførsel av et cytotoksisk middel. Disse metoder er spesifikke eksempler på en bredere metode, behandling av p53-relaterte tumorer ved å hindre binding av IGF til IGFR.
NO981127A 1995-09-14 1998-03-13 Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer NO981127L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US373095P 1995-09-14 1995-09-14
PCT/US1996/014623 WO1997009998A2 (en) 1995-09-14 1996-09-12 Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors

Publications (2)

Publication Number Publication Date
NO981127D0 NO981127D0 (no) 1998-03-13
NO981127L true NO981127L (no) 1998-03-13

Family

ID=21707302

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981127A NO981127L (no) 1995-09-14 1998-03-13 Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer

Country Status (8)

Country Link
US (1) US5840673A (no)
EP (1) EP0871475A2 (no)
JP (1) JP2000502322A (no)
AU (1) AU718451B2 (no)
CA (1) CA2232000A1 (no)
IL (1) IL123383A0 (no)
NO (1) NO981127L (no)
WO (1) WO1997009998A2 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO2000041730A1 (en) 1999-01-13 2000-07-20 Meditech Research Limited A composition and method for the enhancement of the efficacy of drugs
AU3579200A (en) * 1999-02-26 2000-09-14 Saltech I Goteborg Ab Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1
EP1290162A4 (en) * 2000-05-17 2005-08-17 Univ Oregon Health Sciences INDUCTION OF APOPTOSIS AND INHIBITION OF CELL GROWTH BY PROTEIN 4.33 (P4.33)
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AU2001291090B2 (en) * 2000-09-19 2007-05-10 Bioexpertise, Llc Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US20050042303A1 (en) * 2001-08-27 2005-02-24 Brown Tracey Jean Therapeutic protocols
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
EP1435986B1 (en) * 2001-09-18 2008-01-02 Bioexpertise, Llc Igf-binding protein-derived peptide
WO2003068160A2 (en) * 2002-02-13 2003-08-21 The Trustees Of Columbia University In The City Of New York Use of insulin-like growth factor binding protein 3 (igf-bp3) for inhibition of tumor growth
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
WO2004111262A1 (en) * 2003-06-18 2004-12-23 Pharmacia & Upjohn Company Llc Method of identifying a selective chemotherapeutic agent
CA2541015A1 (en) * 2003-10-03 2005-04-14 Genentech, Inc. Igf binding proteins
US20060084603A1 (en) * 2004-08-06 2006-04-20 Irena Kirman IGF-BP3-related methods for inhibiting tumor growth
JPWO2006070577A1 (ja) * 2004-12-28 2008-06-12 独立行政法人海洋研究開発機構 浮沈フロートおよび浮沈フロートの使用方法
EP1912658B1 (en) * 2005-07-27 2017-01-25 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
CN101287475B (zh) * 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT661990E (pt) * 1992-08-26 2002-09-30 Celtrix Pharma Metodo para tratamento sistemico de condicoes catabolicas e de lesoes sistemicas em tecidos
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains

Also Published As

Publication number Publication date
JP2000502322A (ja) 2000-02-29
US5840673A (en) 1998-11-24
NO981127D0 (no) 1998-03-13
AU6975296A (en) 1997-04-01
MX9801704A (es) 1998-05-31
WO1997009998A3 (en) 1997-04-10
WO1997009998A2 (en) 1997-03-20
AU718451B2 (en) 2000-04-13
EP0871475A2 (en) 1998-10-21
IL123383A0 (en) 1998-09-24
CA2232000A1 (en) 1997-03-20

Similar Documents

Publication Publication Date Title
NO981127L (no) Insulin-lignende vekstfaktor bindende protein3 (JGF_BP3) i behandling av P-53 relaterte tumorer
McQUILLAN et al. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage
Allen et al. Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor‐beta, insulin‐like growth factor I, and fibroblast growth factor
Mutt et al. Structure of the Porcine Vasoactive Intestinal Octacosapeptide: The Amino‐Acid Sequence. Use of Kallikrein in Its Determination
Schulz et al. Cloning and expression of guanylin. Its existence in various mammalian tissues.
Heckler et al. Generating disulfides with the Quiescin-sulfhydryl oxidases
AU1955388A (en) Method for potentiating and inhibiting insulin-like growth factor activity
Moise et al. T4 gene 32 protein model for control of activity at replication fork
DK0915910T3 (da) Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse
Gabler et al. Expression pattern of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) system members in bovine corpus luteum endothelial cells during treatment with FGF‐2, VEGF or oestradiol
Cowan et al. NELL-1 increases pre-osteoblast mineralization using both phosphate transporter Pit1 and Pit2
AU2001263215A1 (en) Method for treating cartilage disorders
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
ATE271880T1 (de) Methoden zur behandlung von diabetes
CA2274314A1 (en) Insulin-like growth factor i (igf-i) expression system and methods of use
Gitay-Goren et al. Transforming growth factor beta modulates gonadotropin receptor expression in porcine and rat granulosa cells differently
Burleigh Jr et al. The isolation and primary structure of a peptide containing the oxidation-reduction active cystine of Escherichia coli lipoamide dehydrogenase
DE69435212D1 (de) Behandlung von Diabetes
HOFMANN et al. The primary structure of α-amylase inhibitor Z-2685 from Streptomyces parvullus FH-1641. Sequence homology between inhibitor and α-amylase
WO1998050079A3 (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
Highberger et al. Comparative studies on the amino acid sequence of the α2-CB2 peptides from chick and rat skin collagens
KOTAKI Studies on Insulin: III. On the Structure of the Alanyl Chain of Bonito Insulin
Bernhardt et al. Reactivation studies on putidamonooxin—the monooxygenase of a 4-methoxybenzoate O-demethylase from Pseudomonas putida
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application